Amphastar Pharmaceuticals (AMPH) News Today

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) shares have been volatile following Q2 2025 results, earnings call insights, and various analyst actions. Investors are weighing strong margin performance and earnings beats against flat revenue guidance and a lowered price target.

• Positive Sentiment: In Q2 2025 earnings calls, management highlighted robust margin expansion, solid free cash flow generation, and commercial progress on key injectable and inhalation products. Earnings Call Transcript
• Positive Sentiment: Q2 adjusted EPS of $0.85 beat consensus by $0.14, and revenue of $174.4 million topped estimates, driven by strong cost controls and higher product volumes. Q2 Earnings Beat
• Positive Sentiment: Despite missing certain internal sales targets, shares rallied about 6% as management pointed to cost-saving measures and a strong free cash flow outlook. Misses Q2 Sales Targets, But Stock Soars
• Positive Sentiment: A Zacks report argues Amphastar may be undervalued given its recent earnings momentum and estimate revisions, suggesting potential upside if new product launches gain traction. Are Investors Undervaluing AMPH?
• Neutral Sentiment: Management signaled a flat full-year 2025 revenue outlook amid intensifying generic competition, while advancing U.S. manufacturing expansion to bolster long-term supply chain resilience. Manufacturing Expansion & Flat Outlook
• Neutral Sentiment: A Zacks analysis noted that while Q2 top-line and EPS improved year-over-year, growth rates decelerated compared to prior periods, highlighting the need to monitor product mix and pricing pressures. Key Metrics Analysis
• Negative Sentiment: Analysts at Piper Sandler cut their price target from $30 to $25 and kept a neutral rating, implying limited near-term upside. Piper Sandler Lowers Price Target